

Review

Adjuvant Therapy in Renal Cell Carcinoma: Current Stance and Future Directions

Austin G. Kazarian^a, Neal S. Chawla^b, Ramya Muddasani^b and Sumanta K. Pal^{b,*}

^aUniversity of Iowa Carver College of Medicine, Iowa City, IA, USA

^bDepartment of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Received 18 November 2020

Accepted 6 January 2021

Pre-press 27 January 2021

Abstract. In recent years, incredible progress has been made in the treatment of metastatic renal cell carcinoma, with a paradigm shift from the use of cytokines to tyrosine kinase inhibitors, and more recently, immune checkpoint inhibitors (ICIs). Despite advances in the metastatic setting, effective therapies in the adjuvant setting are a largely unmet need. Currently, sunitinib (Sutent, Pfizer) is the only therapy for the adjuvant treatment of RCC included in the National Comprehensive Cancer Network guidelines, which was approved by the FDA based on the improvement in disease-free survival (DFS) seen in the S-TRAC trial. However, improvement in DFS has not translated into an overall survival (OS) benefit for patients at high-risk of relapse post-nephrectomy, illustrating the need for more effective therapies. This manuscript will highlight attributes of both historical and current drug trials and their implications on the landscape of adjuvant therapy. Additionally, we will outline strategies for selecting patients in whom treatment would be most beneficial, as optimal patient selection is a crucial step towards improving outcomes in the adjuvant setting. This is especially critical, given the financial cost and pharmacological toxicity of therapeutic agents. Furthermore, we will review the design of clinical trials including the value of utilizing OS as an endpoint over DFS. Finally, we will discuss how the incorporation of genomic data into predictive models, the use of more sensitive imaging modalities for more accurate staging, and more extensive surgical intervention involving lymph node dissection, may impact outcomes.

Keywords: Renal cell carcinoma, adjuvant chemotherapy, cytokines, molecular targeted therapy, precision medicine

INTRODUCTION

Renal cell carcinoma (RCC) is estimated to account for 73,750 cases of new cancer diagnoses and 14,830 cancer deaths in the United States in 2020 [1]. Of these, clear cell RCC (ccRCC) is the predominant histological subtype, accounting for approximately 85% of cases. Non-clear cell RCC (non-ccRCC)

comprises the remaining 15% of RCC tumors, of which a significant proportion include papillary (pRCC) or chromophobe (chRCC) subtypes. Incidence of early stage RCC has risen in recent decades due to incidental detection secondary to the increased use of computed tomography scans in practice [2, 3]. From 2004–2015, stage I diagnoses proportionally increased and accounted for approximately 70% of cases, while stage III and IV diagnoses trended downwards to 8% and 11% respectively [4].

Despite statistically significant improvement in early detection, improvement in survival for stage I-III tumors has not been achieved over this time

*Correspondence to: Sumanta K. Pal, MD, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center 1500 East Duarte Road Duarte, CA 91010, USA. Office : +1 626 256 4673; Fax: +1 626 301 8233; E-mail: spal@coh.org.




Fig. 1. Phase III trials completed and ongoing in renal cell carcinoma since the start of the tyrosine kinase era. Abbreviations: RCT, randomized clinical trial.

period. Nephrectomy or ablation can potentially offer patients a cure in early localized disease, however, in stage II and III RCC the risk of recurrence is significant, with 20–40% of patients experiencing a local or distant recurrence [5]. On the other hand, a statistically significant improvement in overall survival (OS) for stage IV disease has been noted, likely secondary to the major advancements in systemic therapy for mRCC [4]. Therapeutic options for mRCC have rapidly progressed from cytokines to targeted therapies with tyrosine kinase inhibitors (TKIs), with a current focus on immune checkpoint inhibitors (ICIs), and combinations thereof. The majority of trial modalities in the adjuvant setting have mirrored those in mRCC (Fig. 1). Understanding key aspects of these trials, reasons for which they may have failed, and future directions in systemic therapy is vital in improving OS within the adjuvant setting. Of note, these agents have varying levels of both pharmacologic and financial toxicities. Subjecting patients at a lower risk of relapse to these treatments must be avoided. Therefore, optimal identification of both high-risk patients, and effective adjuvant therapies remain among the great challenges of the field.

CYTOKINE THERAPY IN THE ADJUVANT SETTING

Initial experimental studies prior to 1990 explored cytotoxic, hormonal, and radiation therapy in mRCC with minimal and unsustained responses [6]. Soon thereafter, it was hypothesized that cytokine therapy could stimulate an immune response against cancer cells [7]. Interferon alpha (IFN- α) and high dose interleukin-2 (IL-2) quickly emerged as front runners, with the latter achieving a 5% sustained complete

response in mRCC, a new milestone at the time [8, 9]. Given this response, IL-2 became an option for monotherapy, while IFN- α was utilized as an adjunctive therapy. Due to their success with mRCC, it was presumed these agents may provide benefit, leading to their exploration via formalized trials within the adjuvant setting [10–12].

Overall, across a constellation of trials, IFN- α and IL-2 did not provide a significant improvement in disease free survival (DFS) or OS. Moreover, they frequently resulted in severe side effects [7, 10]. Pizzocaro et al. investigated adjuvant IFN- α versus placebo in 247 patients with Robson stage II and III RCC, the majority of which were T3a/bN0. This study did not find a significant benefit in five-year DFS or OS [13]. The majority of treated patients developed toxicity, and over a quarter required dose suspension or reduction. Notably, a small number ($n=26$) of pN2/3 patients had a statistically significant reduction in recurrence rate in the experimental arm, observed on univariate analysis. Subsequently, a study by Messing et al. failed to show a statistically significant benefit of adjuvant IFN- α after 10.4 years of follow-up in 283 patients with advanced pT3–4 RCC. Clark et al. conducted a phase III prospective trial exploring adjuvant bolus high dose IL-2 in locally advanced, pT3b–4 or N1–3, or metastatic patients following complete resection of disease prior to enrollment. The study was terminated early due to failure to meet its primary endpoint of 30% improvement in DFS [11]. At interim analysis, there was no difference in DFS or OS observed in the overall cohort, nor in the locally advanced subgroup. The Italian Oncology Group for Clinical Research explored combination therapy with low-dose IL-2 and IFN- α in 303 patients with all histologic subtypes and surgically resectable stages of RCC,

117 which failed to show a statistically significant ben-
118 efit in recurrence free survival (RFS) or OS after five
119 years [7]. The German Cooperative Renal Carcinoma
120 Chemoimmunotherapy Group investigated high dose
121 IL-2, IFN- α , and 5-fluorouracil combination versus
122 observation in the adjuvant setting for 203 patients
123 with locally advanced, pT3b/c-4N0, TXN1-2, or
124 completely resected relapsed or solitary metastatic
125 disease [10]. The trial showed no difference after 4.3
126 years of follow-up in both the overall cohort and in
127 subset analysis with regard to DFS. The intervention
128 cohort experienced significantly decreased survival
129 as compared with the control arm. Another European
130 phase III trial explored this regimen in 309 patients
131 with T3b/c, T4, or TXN1-2 and again found no sig-
132 nificant difference in DFS or OS after 7 years of
133 follow-up [14]. Ultimately the cytokine approach has
134 been largely abandoned in RCC, as drugs with more
135 efficacy, improved safety, and tolerability have come
136 to the forefront.

137 TARGETED THERAPY IN THE 138 ADJUVANT SETTING

139 As the biology and tumor microenvironment of
140 various cancers came to be better understood in
141 the early 2000s, several molecules were developed
142 with the aim of disrupting the molecular functions
143 that facilitate tumor growth and invasion. Small
144 molecules, antibodies, hormones, and interfering
145 RNA (iRNA) are examples of the class of medica-
146 tions known as targeted therapy [15]. Amongst the
147 small molecule compounds are the tyrosine kinase
148 inhibitors (TKIs). Mutations in the Von Hippel-
149 Lindau (*VHL*) gene are implicated in the majority of
150 ccRCC tumors [16, 17]. The *VHL* tumor-suppressor
151 protein is a component of the E3 ubiquitin ligase com-
152 plex which under normal conditions promotes the
153 degradation of hypoxia inducible factor 1- α (HIF1 α),
154 a transcriptional regulator of the angiogenesis path-
155 way. HIF1- α promotes the activation of vascular
156 endothelial growth factor (VEGF) and drives platelet
157 derived growth factor (PDGF) production. Therefore,
158 mutations in this pathway often lead to aberrantly
159 persistent angiogenesis and tumorigenesis. TKIs that
160 specifically inhibit VEGF were developed and came
161 to be known as VEGF-TKIs [18]. The mammalian
162 target of rapamycin (mTOR), a cell proliferation
163 pathway frequently hyperactive in RCC, was also
164 a subject of targeted therapy, with everolimus and
165 temsirolimus eventually gaining FDA approval in
166 mRCC [19].

167 Early stage trials established the efficacy of VEGF-
168 TKIs, but revealed the potential toxicities seen with
169 this class of medications. Common side effects asso-
170 ciated with this class include hypertension, diarrhea,
171 fatigue, mucosal inflammation, and palmar-plantar
172 erythrodysesthesia and hand-foot syndrome [20]. A
173 phase III trial comparing sunitinib with IFN- α in
174 750 mRCC patients showed a significant benefit in
175 DFS and OS [21]. Further studies using VEGF
176 inhibitors including pazopanib, axitinib were also
177 approved for mRCC based on significant DFS [22,
178 23]. Although a number of trials attempted to utilize
179 VEGF-TKIs, and mTOR inhibitors in the adjuvant
180 setting, results have been far less fruitful.

181 Within the realm of targeted therapy, only S-TRAC
182 (sunitinib vs placebo) has shown improvement in
183 DFS, and thereby has been approved for treatment
184 in the adjuvant setting, despite its increased inci-
185 dence of grade >3 adverse effects [21]. The results of
186 ASSURE (sunitinib vs sorafenib vs placebo), PRO-
187 TECT (pazopanib vs placebo), SORCE (sorafenib vs
188 placebo), and ATLAS (axitinib vs placebo) suggest
189 no improvement in DFS with adjuvant therapy [19,
190 22–24].

191 The randomized phase III trial ASSURE (Sunitinib
192 Malate or Sorafenib Tosylate in Treating Patients
193 with Kidney Cancer that was Removed by Surgery)
194 launched soon after regulatory approval of sunitinib
195 and sorafenib for mRCC, and sought to explore these
196 targeted therapies in the high-risk adjuvant setting
197 [25]. 1943 patients, of any histological subtype, were
198 randomized 1:1:1 to receive sunitinib 50 mg daily,
199 sorafenib 800 mg daily, or placebo. Ultimately, no
200 significant difference was observed in DFS between
201 treatment groups. However, there was greater toxicity
202 seen in the treatment arms, with a significantly greater
203 incidence of hypertension and hand-foot syndrome.
204 Discontinuation due to adverse events or patient with-
205 drawal occurred in 44% and 45% of participants in
206 the sunitinib and sorafenib arms respectively, com-
207 pared to 11% on placebo. This led to a protocol
208 amendment for dose reductions from planned levels.
209 Subsequently, a subgroup analysis found no differ-
210 ence in DFS regardless of dosage. The ASSURE trial
211 included variable histology, with 20% of patients hav-
212 ing non-ccRCC. Yet, no difference was observed in
213 ccRCC or non-ccRCC cohorts. Despite the negative
214 outcome seen in this trial, two subsequent studies
215 exploring each agent individually in the adjuvant
216 setting were launched: S-TRAC (A Clinical Trial
217 Comparing Efficacy And Safety of Sunitinib Versus
218 Placebo For the Treatment of Patients at High Risk

of Recurrent Renal Cell Cancer) for sunitinib and SORCE (Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer) for sorafenib [26].

In contrast to the ASSURE trial, the S-TRAC trial enrolled patients with only clear cell histology who were defined as high risk per the UCLA integrated staging system (UISS) [26]. A total of 615 patients were enrolled and randomized to receive sunitinib or placebo. Results demonstrated a significant DFS benefit with sunitinib over placebo (6.8 versus 5.6 years, (95% CI 5.8-not reached) (95%CI 3.8–6.6) respectively, $p=0.03$). This was the first and only positive trial investigating TKI agents in the adjuvant setting. A significant proportion of patients required dose reductions or interruptions: 34.3% and 46.4% with sunitinib versus 2.0% and 13.2% with placebo, respectively. The observed benefit in DFS held true across various subgroup analyses. However, longer follow-up has shown that improvement in DFS did not correlate to a difference in OS benefit between sunitinib or placebo (median OS not reached at 6.6 versus 6.7 years respectively, (HR 0.92, 95% CI 0.66–1.28; $p=0.6$) [26].

The S-TRAC results were particularly interesting given the lack of DFS benefit identified for sunitinib in the ASSURE trial [25, 26]. The subtle differences between both study populations were scrutinized due to their divergent outcomes. It was hypothesized that this may be due to the selection of a high-risk ccRCC cohort in the S-TRAC trial. The ASSURE authors investigated this question by analyzing the high-risk clear cell RCC cohort in a subset analysis; however, there remained no significant difference in either DFS or OS [25]. The reasons for these differing results are still not completely understood and continue to be controversial.

The SORCE trial recruited 1711 intermediate or high-risk patients, as determined by Leibovich classification of 3–11, who were randomized 2:3:3 to placebo, one year of sorafenib followed by two years of placebo, or three years of sorafenib [24]. The study included both ccRCC and non-ccRCC histology. In the most recently reported efficacy analysis of placebo versus three years of sorafenib, no difference was observed in DFS or OS for the overall, high-risk only, or clear cell RCC only cohorts [24]. As with other trials investigating targeted therapy, a significant proportion of patients experienced side effects, leading to amendment of the trial protocol to reduce the dosage of sorafenib. Despite dose reductions, over half of patients stopped treatment early and

nearly a quarter experienced grade three hand-foot syndrome.

Given the mixed results of other VEGF-TKI trials in this setting, the PROTECT (A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma) trial sought to study compare pazopanib versus placebo following partial or radical nephrectomy in patients at high risk for recurrence [23]. The study allowed only ccRCC patients who were pT2N0M0: pT3-4 of any grade N0m0 or any pTN1M0. Comparatively, the risk of recurrence in the PROTECT study was between that of the S-TRAC and ASSURE study populations [23, 25, 26]. The starting dosage of pazopanib was reduced from 800 mg to 600 mg because a safety review revealed unexpectedly high rates of drug discontinuation due to adverse effects [23]. The primary endpoint was DFS of pazopanib 600 mg. OS and PFS of the 800 mg dosage were assessed as secondary endpoints. The protocol allowed for increase of dosage to 800 mg after 8–12 weeks if tolerated. Primary analysis was done following 350 DFS events, which demonstrated no significant difference in DFS between the 600 mg trial arm and placebo. However, a 33.7% reduction in risk of recurrence or death was observed for those receiving 800 mg dosage ($n=189$ patients), with median DFS not yet reached in the experimental group, and 54.0 months in the placebo group ($p=.008$). Investigators cautioned that the difference in DFS between the 600 mg and 800 mg groups may be attributable to superior DFS in the placebo arm of the former as compared to the latter. Notably, patients with higher plasma trough levels of pazopanib tended towards longer DFS. OS at the time of DFS analysis did not significantly differ at either dose level.

The ATLAS trial, another trial restricted to ccRCC patients, explored the novel TKI axitinib versus placebo in 724 patients with advanced disease with similar inclusion criteria as the PROTECT trial [22, 23]. ATLAS was discontinued due to futility, failing to show a difference in the primary endpoint of DFS [22]. A subgroup analysis was conducted evaluating low-risk versus high-risk patients. Although, a DFS benefit was seen with investigator assessed outcomes in the high-risk group (HR = 0.641, $p=0.0051$), this benefit was insignificant per independent review facility assessment (HR 0.735, $p=0.0704$). Survival data were not mature at the time of analysis. While the incidence of adverse events was similar between treatment and placebo groups, increased grade 3–4 events and discontinuation due to adverse events were noted in the experimental group. It is notable that the

Table 1
Randomized clinical trials investigating adjuvant tyrosine kinase inhibitors to in renal cell carcinoma

Trial	Experimental Therapy	Therapy Duration (years)	Completion	Enrollment	Histology	Endpoint	Statistically Significant?	Eligibility
ASSURE	Sunitinib	1	2010	1943	Any	DFS	No*	≥T1bNXM0
SORCE	Sorafenib	3	2012	1656	Any	DFS	No	Leibovich 3–11
S-TRAC	Sunitinib	1	2016	674	ccRCC	DFS	Yes	High-risk per UISS
PROTECT	Pazopanib	1	2016	1538	ccRCC	DFS	No†	pT2, pT3-4N0, or node positive disease
ATLAS	Axitinib	3	2017	592	ccRCC	DFS	No	pT2, pT3-4N0, or node positive disease
EVEREST	Everolimus	1	Estimated 2021	1545	Any	DFS	TBD	Intermediate (pT2-3aN0) or high (pT3a-4N0-1) risk

*Subset analysis of high risk ccRCC patients similar to S-TRAC failed to show DFS difference. †Subset analysis of patients receiving 800 mg dose showed a significant DFS benefit. Abbreviations: ccRCC, clear cell renal cell carcinoma; DFS, disease-free survival; UISS, UCLA integrated scoring system; TBD, to be determined.

majority (73%) of the study population were of Asian heritage, which may have impacted its applicability to other patient groups.

Additionally, adjuvant VEGF-TKI therapy has been explored in the related population of patients with limited metastatic disease undergoing radical nephrectomy and metastasectomy. E2810, a phase III trial investigating 800 mg pazopanib for one year in patients with no evidence of disease following metastasectomy, failed to find a benefit in DFS, with limited data supporting a trend of worse OS in those receiving pazopanib [27]. Similarly, the phase II RESORT trial compared RFS in patients randomized to 800 mg sorafenib versus observation for one year of planned treatment. After five years resulting in 69 accrued patients, the trial was closed early and analysis failed to reveal a benefit in RFS between groups. The RESORT trial also reported toxicity data consistent with other VEGF-TKI trials, revealing an approximately eight-fold increase in grade 3 toxicities in the sorafenib arm of the study [28].

Trials exploring mTOR inhibitors in the adjuvant setting are lacking. The ongoing EVEREST trial (NCT01120249) is seeking to shed light on this approach [19]. This trial is exploring one year of adjuvant everolimus versus placebo of the same duration, in patients with any histological RCC subtypes. This study includes patients at high and intermediate risk of recurrence. The primary endpoint is DFS. A safety study has been reported that suggests a continued trend of treatment limiting toxicity in targeted therapy, as 39% of patients on experimental therapy have prematurely discontinued treatment. Medication trough levels were also measured and did correlate with the development of adverse events.

Results regarding DFS are not yet mature, but when available will likely determine if any further exploration of this therapeutic class as adjuvant therapy is warranted.

Trials of targeted therapy in RCC have generally failed to show a statistical or clinical benefit for patients (Table 1). The use of these agents frequently accompanied by the high cost of toxicity. The S-TRAC study remains an outlier amongst this group of trials and its application in clinical practice is unclear, a fact reflected in governing guidelines. The National Comprehensive Cancer Network (NCCN) recommends adjuvant sunitinib with a category 2B designation, indicating lower-level evidence and a lack of uniform consensus [29]. The European Association of Urology does not recommend adjuvant sunitinib, based on high quality systematic review and homogeneity of randomized clinical trials (level of evidence 1A) [30]. Furthermore, this therapy has not been approved by the European Medicines Agency in the adjuvant setting. A systematic review and pooled analysis of ASSURE, S-TRAC, and PROTECT supported general trends, with no consistent effect on DFS or OS of adjuvant VEGF therapy despite a significant incidence of adverse events [31]. The pooled analysis showed that out of every ten patients treated with VEGF therapy, only one was likely to experience improvement in DFS. In conclusion, while TKI therapy may continue to play a role in the management of metastatic disease, current evidence suggests that observation may better serve patients over TKI therapy in the adjuvant setting. However, the newest class of therapy in RCC, immune checkpoint inhibitors, may offer benefit in the adjuvant space.

Table 2
Randomized clinical trials planned to explore checkpoint inhibitors in renal cell carcinoma

Trial	Therapy	Inhibitor Type(s)	Therapy Duration (years)	Completion	Planned Enrollment	Histology	Endpoint
ImMotion010*	Atezolizumab	PD-L1	1	2022	664	Any	DFS
Keynote-564*	Pembrolizumab	PD-1	1	2022	950	ccRCC	DFS
PROSPER*	Nivolumab	PD-1	0.75 [†]	2023	805	Any	EFS
Checkmate 914	Nivolumab; Nivolumab + Ipilimumab	PD-1; PD-1 + CTLA-4	2	2023	1600	ccRCC	DFS
RAMPART	Durvalumab; Dur- volumab + Tremelimumab	PD-L1; PD-L1 + CTLA-4	1	2024	1750	Any	DFS; OS

*Metastasectomy patients eligible. [†]Patients receive one dose neoadjuvant and 9 doses adjuvant. Abbreviations: PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ccRCC, clear cell renal cell carcinoma; DFS, disease-free survival; OS, overall survival; event-free survival, EFS.

THE IMMUNE CHECKPOINT ERA

Immune checkpoint inhibitors have truly transformed therapy across a number of solid tumors, most notably in RCC. Not unlike the rationale behind the cytokine era, checkpoint inhibition again involves modulation of the immune system to fight cancer. These agents block signals which perpetuate downregulation of T-cell action and prevent normal antitumor functions [32]. Two sets of checkpoint inhibitor interactions are targeted by these monoclonal antibody agents: programmed death protein 1 (PD-1) with its ligand (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) with its ligand (CD80/86). Agents in this class have rapidly progressed from investigational to first line therapy in mRCC, displaying both increased efficacy and improved side effect profiles than previous targeted agents [33–35]. Ipilimumab (Yervoy, Bristol-Meyers Squibb, a CTLA-4 inhibitor) and nivolumab (Opdivo, Bristol-Meyers Squibb, a PD-1 inhibitor) combination therapy is a preferred first line regimen in the poor prognostic group in mRCC, as well as in subsequent therapy, with a category 1 recommendation for both scenarios [29]. As with previous generations of therapies, the natural question of efficacy in the adjuvant space has emerged. Five phase III randomized clinical trials are currently exploring this very question (Table 2).

ImMotion 010 (A Study of Atezolizumab as Adjuvant Therapy in Participants With RCC at High Risk of Developing Metastasis Following Nephrectomy) is a large trial of atezolizumab (Tecentriq, Genentech, a PD-L1 inhibitor), versus placebo, with an accrual goal of over 750 patients [36]. Eligible patients include those at high risk for recurrence following radical or partial nephrectomy or following

metastasectomy without residual disease on imaging following surgery. Primary endpoint is DFS by independent review, with secondary endpoints including OS, and DFS of patients with $\geq 1\%$ PD-L1 expression. Results are expected in 2022.

Keynote-564 (Safety and Efficacy Study of Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy) is investigating the potential of pembrolizumab (Keytruda, Merck, a PD-1 inhibitor), in patients with intermediate-high risk or high-risk clear cell histology, sarcomatoid features and without evidence of disease following nephrectomy [37]. Those with a few soft tissue metastatic lesions would be allowed if lesions can be removed with a synchronous or metachronous metastasectomy (at the time of, or one year following nephrectomy, respectively). Approximately 950 patients will be randomized to one year of pembrolizumab or placebo. Patients are stratified into intermediate or high risk, based on TNM and Fuhrman grade criteria, or completely resected metastatic disease. DFS by investigator assessment will serve as the primary endpoint. OS, safety and tolerability will be included amongst the secondary endpoints. Reported results anticipated in 2022.

PROSPER (Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy) is a phase 3 unblinded study of nivolumab in the perioperative setting versus nephrectomy followed by observation [38]. Patients in the experimental arm will undergo one neoadjuvant nivolumab dose, followed by nine cycles of adjuvant nivolumab followed by observation (a prior version of the protocol stated 2 neoadjuvant doses, and up to 12 cycles of adjuvant therapy). The PROSPER neoadjuvant-adjuvant combination protocol is unique among contemporary trials in kidney cancer. While the rationale for pure

465 adjuvant therapy is to eliminate or halt the growth
466 of residual tumor cells following surgery, the ratio-
467 nale behind the neoadjuvant dosing is to prime T-cells
468 against the primary tumor in an environment rich
469 with neoantigens [39]. Theoretically, natural immu-
470 nity would thus be heightened following operation,
471 which, in combination with further adjuvant therapy,
472 may lead to robust clearance of residual micrometas-
473 tases and a maintained immune memory for tumor
474 antigens. Planned enrollment is 805 patients and any
475 histology may be included. Primary endpoint is event
476 free survival, defined as recurrence or death from
477 any cause up to 10 years, with primary data analysis
478 estimated for 2023.

479 RAMPART (Renal Adjuvant MultiPle Arm Ran-
480 domised Trial) is a multi-arm trial of 1 year of
481 observation following surgery (arm A) versus single
482 agent durvalumab (Imfinzi, AstraZeneca, a PD-L1
483 inhibitor) (arm B) versus doublet therapy with dur-
484 valumab with tremelimumab (Optune, Novocure, a
485 CTLA-4 inhibitor) (arm C) [40]. Primary endpoints
486 are DFS and OS for arms B and C versus arm
487 A. Patients with Leibovich score 3–11 (indicating
488 intermediate to high risk of recurrence following
489 nephrectomy) of any histology are eligible [40].
490 Notably, those with an intermediate Leibovich score
491 of 3–5 will be enrolled up to three years of the start
492 of the trial or until this group represents 25% of the
493 study population. Recruitment target is 1750 patients
494 and with results expected in 2024.

495 CheckMate 914 (A Study Comparing the Com-
496 bination of Nivolumab and Ipilimumab Versus
497 Placebo in Participants With Localized Renal Cell
498 Carcinoma) is investigating nivolumab alone or com-
499 bination nivolumab and ipilimumab, compared to
500 placebo [34]. Randomization in part A of the trial
501 will be 1:1 nivolumab+ipilimumab to placebo for
502 2 years. Part B randomization will be 1:1:2, with
503 nivolumab plus ipilimumab placebo serving as the
504 third arm. Eligible patients include those at high risk
505 for relapse following nephrectomy. The aforemen-
506 tioned interventions are planned for 24 months or
507 first DFS event, treatment limiting toxicity, or consent
508 withdrawal. Only patients with predominantly clear
509 cell histology are eligible. This study has a planned
510 enrollment of 1600 with anticipated completion in
511 2023. Primary and secondary endpoints are DFS and
512 OS by independent review, respectively.

513 The next generation of adjuvant trials are posi-
514 tioned to answer a number of novel questions, in
515 addition to exploring the role of adjuvant check-
516 point inhibitors. ImMotion010, Keynote-564, and

517 PROSPER all allow enrollment of patients who are
518 status post metastasectomy, a previously unexplored
519 area for adjuvant therapy [36–38]. ImMotion010,
520 PROSPER, and RAMPART have generous histology
521 inclusion criteria, allowing for subgroup analysis of
522 adjuvant therapy in selected non-ccRCC cohorts [36,
523 38, 40]. Checkmate 914 and RAMPART incorporate
524 experimental arms with dual CTLA-4 and PD block-
525 ade, a combination with previously demonstrated
526 efficacy in advanced RCC [34, 40]. With the structure
527 of these trials, monotherapy and combination therapy
528 can be directly compared.

529 NOVEL THERAPEUTIC APPROACHES

530 Parallel to the evolution of classical generations
531 of cytokine, targeted, and checkpoint inhibitor ther-
532 apy, novel approaches have been tested. A number
533 of vaccines have been explored as adjuvant ther-
534 apy for RCC. Autologous tumor cells incubated with
535 Bacillus Calmette-Guerin (BCG) twice-injected after
536 surgery was compared to placebo without statisti-
537 cally significant differences in DFS or OS at 5 years
538 [41]. Another study explored an autologous vac-
539 cine complexly created from patient lymph tissue
540 incubated in interferon gamma and injected in six
541 doses adjuvant to surgery. It showed an improvement
542 in DFS over placebo after five years of follow-up
543 ($p = 0.02$) [42]. This trial has been subject to a num-
544 ber of criticisms, however, including the proportion
545 of ccRCC patients being higher in the experimental
546 group, as well as trial conduction parameters. Given
547 the cost and complexity of the treatment, this vac-
548 cine treatment has been abandoned [40]. Another
549 vaccine based on heat-shock protein (glycoprotein-
550 96)-peptide complex, HSPPP-96, was investigated
551 in a phase III trial which showed no difference in
552 RFS [43]. Although promising in a phase II trial
553 of mRCC, the autologous RNA-modulated dendritic
554 cell vaccine AGS-003 phase III trial (NCT01582672)
555 in mRCC was terminated due to lack of efficacy
556 which lead to termination of investigation of this ther-
557 apy in the neoadjuvant setting (NCT02170389) [41].

558 The ARISER trial investigated the monoclonal
559 antibody girentuximab targeting carbonic anhydrase
560 IX, a surface glycoprotein commonly expressed on
561 ccRCC tumors [44]. The trial recruited 864 patients
562 with ccRCC tumors with high risk for recurrence
563 defined as T2G3 + N0M0, T3-4NXM0, or TXN+M0.
564 No clinical benefit in DFS, with a median follow-
565 up of 6.0 years, or OS, with median follow-up not

566 reached, was observed. Drug-related and serious ad-
567 verse events were comparable between experimental
568 and placebo arms.

569 CURRENT CHALLENGES AND FUTURE 570 DIRECTIONS

571 With the tradeoff of adverse events and minimal, if
572 any, benefit of therapy, selecting the optimal patients
573 in which to administer adjuvant therapy is of the
574 utmost importance. Potential areas of focus include
575 improvement of current predictive models, improved
576 surgical techniques incorporating lymph node dissec-
577 tion, and the incorporation of more sensitive imaging
578 in identifying patients who would benefit from lymph
579 node dissection [45].

580 Previously, risk of recurrence was stratified uti-
581 lizing several factors including tumor size, grade,
582 necrosis, and lymph node involvement [46–48].
583 Using these elements, several predictive models have
584 been developed. One of the initial models, the SSIGN
585 score, developed by the Mayo Clinic, included stage,
586 size, grade and necrosis [46]. Later, this model was
587 modified to include LN involvement, known as the
588 Leibovich prognosis score. The University of Cali-
589 fornia Los Angeles Integrated Staging System (UISS)
590 incorporates presence of metastasis, Fuhrman nuclear
591 grade and the Eastern Cooperative Oncology Group
592 (ECOG) performance status [49]. These predictive
593 models are often utilized to select patients at high risk
594 for recurrence thereby determining who would bene-
595 fit from adjuvant therapy. Other nomograms include
596 the Union for Initial Cancer, Memorial Sloan Ketter-
597 ing Cancer Center nomogram, and the GRANT score
598 [50]. However, they often contain limitations and lack
599 prospective validation [45].

600 Despite their flaws, these predictive models are
601 often utilized as they are relatively simple and have
602 little to no additional cost. Novel methods using
603 genetic sequencing offer improved accuracy and
604 potentially wider application; however, they are hin-
605 dered by cost and availability. These methods largely
606 appear to be improved when combined with current
607 clinical scoring systems. Several studies have sought
608 to establish gene mutational signatures as prognos-
609 tic tools in RCC using next generation sequencing
610 (NGS). Brooks *et al* developed a 34 gene panel,
611 which was validated using RNA sequencing data
612 from the Cancer Genome Atlas database. Patients in
613 the poor risk group were found to have more fre-
614 quent and earlier recurrence, were at nearly three

615 times higher risk of disease specific death, and more
616 than twice as likely to experience all cause-mortality
617 [51]. Rini et al. developed a 16 gene panel to pre-
618 dict clinical outcomes of stage I-III ccRCC. Using
619 reverse-transcription PCR, over 500 genes were iden-
620 tified that correlated with recurrence free survival
621 (RFS) from a database of nearly 1000 patients [52]. 11
622 were ultimately selected via statistical analysis, with
623 5 other reference genes for a total of 16 genes, based
624 upon which a recurrence score was calculated. This
625 approach was validated using the cohort data from
626 the S-TRAC trial, and was found to be predictive of
627 RFS, time to recurrence, and renal cancer-specific
628 survival. The cell cycle proliferation (CCP) score
629 was developed by Morgan et al., by identifying
630 genes involved in cellular proliferation using an RNA
631 expression assay. The CCP score predicted recur-
632 rence and disease-specific mortality in these patients
633 [53]. When used with the Karakiewicz nomogram, a
634 composite score was developed, which reliably dif-
635 ferentiated low-risk and high-risk patients. Notably,
636 this study included patients with chromophobe and
637 papillary histologies in addition to ccRCC. Long
638 non-coding RNA (LncRNA) has been found to play
639 key roles in tumorigenesis and tumor progression.
640 Qu et al. identified four LncRNAs associated with
641 recurrence in RCC that stratified patients as low or
642 high risk for recurrence and outperformed TNM and
643 SSIGN scores. Additionally, studies have illustrated
644 cell tumor DNA (ctDNA) has the potential to function
645 as a surveillance biomarker in patients with local-
646 ized RCC. A study by Al-Qassab et al. found 67% of
647 patients with RCC ($n = 30$) had detectable mutations
648 in more than gene via ctDNA NGS assay, as com-
649 pared with 3.1% of individuals in their healthy control
650 group ($n=32$) [54]. The incorporation of genomic
651 data in conjunction with current predictive scores in
652 RCC has improved accuracy in identifying patients
653 at higher risk.

654 Another approach requiring further exploration is
655 the widespread use of lymph node dissection dur-
656 ing nephrectomy, even in patients without significant
657 risk factors for nodal involvement. The European
658 Organization for Research and Treatment of Can-
659 cer (EORTC) randomized phase 3 trial 30881, which
660 compared nephrectomy versus nephrectomy with
661 routine lymph node dissection, showed no differ-
662 ence in OS or PFS benefit between both groups
663 [55]. Based on this study, NCCN guidelines recom-
664 mend that lymph node dissection be completed only
665 when enlarged lymph nodes are present on preop-
666 erative imaging or palpated during surgery which

allows variability in nodal analysis [29]. However, the EORTC study did not look at the use of subsequent adjuvant treatment in those who were found to be node positive. By performing routine lymph node dissection, we may be able to better stratify patients and identify a larger subset which are at higher risk of distant recurrence, and accordingly may benefit from adjuvant treatments.

Currently, cross sectional imaging with CT scan is the standard imaging modality used in the staging evaluation of patients prior to nephrectomy. The potential use of more sensitive imaging techniques such as FDG-PET or 18F-FDG PET may be a useful tool in the preoperative evaluation of patients for increased detection of nodal involvement [45]. Although the utility of conventional FDG-PET imaging is debatable in RCC, novel PET methods may prove useful in identifying ideal candidates for immunotherapy. Currently under investigation are PET tracers tracking CD8, and reports exist of PET tracers labeling atezolizumab and other checkpoint inhibitors [56–58]. These novel imaging approaches may increase imaging sensitivity with downstream effects of identifying a greater number of patients with metastatic disease at diagnosis and allowing treatment optimization.

As recurrence risk in trial design evolves to incorporate genetics, so too must the primary aims be evaluated. The majority of adjuvant studies in RCC have used DFS as a primary outcome, as are many of the current adjuvant studies investigating checkpoint inhibitors. However, a meta-analysis of trials in the targeted era found that DFS correlated only moderately with OS, suggesting its ability to serve as a surrogate was not particularly strong [59].

CONCLUSION

Improving patient selection for therapy will likely position future drug trials in the adjuvant RCC setting for greater success. Further development of methods that combine clinical data with gene mutation data likely hold the most promise. However, optimal patient selection is futile without improving adjuvant therapeutic modalities. Despite conferring improved patient outcomes in mRCC, neither cytokine nor TKI agents have shown consistent benefit in the adjuvant setting. The one exception is the S-TRAC trial, which illustrated a 1-year DFS, but lacked OS benefit, and was burdened by notably high toxicity rates. Furthermore, these findings were not reproduced in a

subsequent subset analysis. Other trials with various TKIs have also failed to show benefit in the adjuvant setting. VEGF-TKIs, by their very nature may not be a fruitful strategy in this arena. Data from phase III trials testing everolimus and several checkpoint inhibitors are eagerly awaited and have the potential to provide the long-sought value of adjuvant therapy of RCC.

ACKNOWLEDGMENTS

The authors have no acknowledgments

FUNDING

The authors report no funding.

AUTHOR CONTRIBUTIONS

Austin G. Kazarian: conception, literature review, interpretation of data, revisions

Neal S. Chawla: conception, literature review, interpretation of data, revisions

Ramya Muddasani: conception, literature review, interpretation of data, revisions

Sumanta K. Pal: conception, literature review, interpretation of data, revisions

CONFLICT OF INTEREST

AGK, NSC, and RM have no disclosures.

SKP reports consultancy fees from Pfizer, Inc, Novartis, Aveo, Genentech, Exelixis, Bristol Myers Squibb, Astellas Pharmaceuticals, Eisai, Roche, and Ipsen, and honoraria from Novartis, Medivation, and Astellas Pharmaceuticals.

REFERENCES

- [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70:7-30. <https://doi.org/10.3322/caac.21590>.
- [2] Touloupidis S, Papanthanasou A, Kalaitzis C, Fatles G, Manavis I, Rombis V. Renal cell carcinoma: The influence of new diagnostic imaging techniques on the size and stage of tumors diagnosed over the past 26 years. *Int Urol Nephrol* 2006;38:193-7. <https://doi.org/10.1007/s11255-005-4762-4>.
- [3] Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: Analysis of the National Cancer Data Base. *Cancer* 2008;113:78-83. <https://doi.org/10.1002/ncr.23518>.
- [4] Patel HD, Gupta M, Joice GA, Srivastava A, Alam R, Allaf ME, et al. Clinical Stage Migration and Survival for

- Renal Cell Carcinoma in the United States. *Eur Urol Oncol* 2019;2:343-8. <https://doi.org/10.1016/j.euo.2018.08.023>.
- [5] Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, et al. GUIDELINES FOR THE SURVEILLANCE OF LOCALIZED RENAL CELL CARCINOMA BASED ON THE PATTERNS OF RELAPSE AFTER NEPHRECTOMY. *J Urol* 2004;172:58-62. <https://doi.org/10.1097/01.ju.0000132126.85812.7d>.
- [6] Bloom HJG. Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer. *Br J Cancer* 1971;25:250-65. <https://doi.org/10.1038/bjc.1971.31>.
- [7] Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, et al. Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon- α (IFN- α) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC). *J Immunother* 2014;37:440-7. <https://doi.org/10.1097/CJI.000000000000055>.
- [8] Interferon- α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. *The Lancet* 1999;353:14-7. [https://doi.org/10.1016/S0140-6736\(98\)03544-2](https://doi.org/10.1016/S0140-6736(98)03544-2).
- [9] Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1995;13:688-96. <https://doi.org/10.1200/JCO.1995.13.3.688>.
- [10] Atzpodiën J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). *Br J Cancer* 2005;92:843-6. <https://doi.org/10.1038/sj.bjc.6602443>.
- [11] Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant High-Dose Bolus Interleukin-2 for Patients With High-Risk Renal Cell Carcinoma: A Cytokine Working Group Randomized Trial. *J Clin Oncol* 2003;21:3133-40. <https://doi.org/10.1200/JCO.2003.02.014>.
- [12] Messing EM, Manola J, Wilding G, Probert K, Fleischmann J, Crawford ED, et al. Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial. *J Clin Oncol* 2003;21:1214-22. <https://doi.org/10.1200/JCO.2003.02.005>.
- [13] Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, et al. Interferon Adjuvant to Radical Nephrectomy in Robson Stages II and III Renal Cell Carcinoma: A Multicentric Randomized Study. *J Clin Oncol* 2001;19:425-31. <https://doi.org/10.1200/JCO.2001.19.2.425>.
- [14] Aitchison M, Bray CA, Van Poppel H, Sylvester R, Graham J, Innes C, et al. Adjuvant 5-fluorouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. *Eur J Cancer* 2014;50:70-7. <https://doi.org/10.1016/j.ejca.2013.08.019>.
- [15] Baudino T. Targeted Cancer Therapy: The Next Generation of Cancer Treatment. *Curr Drug Discov Technol* 2015;12:3-20. <https://doi.org/10.2174/1570163812666150602144310>.
- [16] Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. *Nat Genet* 1994;7:85-90. <https://doi.org/10.1038/ng0594-85>.
- [17] Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, et al. Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. *Clin Cancer Res* 2008;14:4726-34. <https://doi.org/10.1158/1078-0432.CCR-07-4921>.
- [18] Peña C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. *Clin Cancer Res Off J Am Assoc Cancer Res* 2010;16:4853-63. <https://doi.org/10.1158/1078-0432.CCR-09-3343>.
- [19] Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, et al. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). *Kidney Cancer Clifton Va* 2019;3:111-8. <https://doi.org/10.3233/KCA-180049>.
- [20] Hayman SR, Leung N, Grande JP, Garovic VD. VEGF Inhibition, Hypertension, and Renal Toxicity. *Curr Oncol Rep* 2012;14:285-94. <https://doi.org/10.1007/s11912-012-0242-z>.
- [21] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. *J Clin Oncol* 2009;27:3584-90. <https://doi.org/10.1200/JCO.2008.20.1293>.
- [22] Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. *Ann Oncol* 2018;29:2371-8. <https://doi.org/10.1093/annonc/mdy454>.
- [23] Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, et al. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. *J Clin Oncol Off J Am Soc Clin Oncol* 2017;35:3916-23. <https://doi.org/10.1200/JCO.2017.73.5324>.
- [24] Eisen TQG, Frangou E, Smith B, Ritchie A, Kaplan RS, Oza B, et al. Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL. *Ann Oncol* 2019;30:v891-2. <https://doi.org/10.1093/annonc/mdz394.050>.
- [25] Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, et al. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. *JAMA Oncol* 2017;3:1249. <https://doi.org/10.1001/jamaoncol.2017.0076>.
- [26] Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, et al. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. *N Engl J Med* 2016;375:2246-54. <https://doi.org/10.1056/NEJMoa1611406>.
- [27] Appleman LJ, Puligandla M, Pal SK, Harris W, Agarwal N, Costello BA, et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with

- metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). *J Clin Oncol* 2019;37:4502-4502. https://doi.org/10.1200/JCO.2019.37.15_suppl.4502.
- [28] Procopio G, Apollonio G, Cognetti F, Miceli R, Milella M, Mosca A, et al. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. *Eur Urol Oncol* 2019;2:699-707. <https://doi.org/10.1016/j.euo.2019.08.011>.
- [29] Kidney Cancer (Version 1.2021): National Comprehensive Cancer Network; [Available from: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf n.d. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (accessed September 29, 2020).
- [30] Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. *Eur Urol* 2019;75:799-810. <https://doi.org/10.1016/j.eururo.2019.02.011>.
- [31] Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, et al. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. *Eur Urol* 2018;74:611-20. <https://doi.org/10.1016/j.eururo.2018.05.002>.
- [32] Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* 2012;24:207-12. <https://doi.org/10.1016/j.coi.2011.12.009>.
- [33] Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015;373:1803-13. <https://doi.org/10.1056/NEJMoa1510665>.
- [34] Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018;378:1277-90. <https://doi.org/10.1056/NEJMoa1712126>.
- [35] Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. *Lancet Lond Engl* 2019;393:2404-15. [https://doi.org/10.1016/S0140-6736\(19\)30723-8](https://doi.org/10.1016/S0140-6736(19)30723-8).
- [36] Uzzo R, Bex A, Rini BI, Albiges L, Suarez C, Donaldson F, et al. A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010). *J Clin Oncol* 2017;35:TPS4598-TPS4598. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4598.
- [37] Choueiri TK, Quinn DI, Zhang T, Gurney H, Doshi GK, Cobb PW, et al. KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. *J Clin Oncol* 2018;36:TPS4599-TPS4599. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS4599.
- [38] Harshman LC, Puligandla M, Haas NB, Allaf M, Drake CG, McDermott DF, et al. PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). *J Clin Oncol* 2019;37:TPS4597-TPS4597. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS4597.
- [39] Broderick SR. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer. *Thorac Surg Clin* 2020;30:215-20. <https://doi.org/10.1016/j.thorsurg.2020.01.001>.
- [40] Powles T, O'Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. *JAMA Oncol* 2017;3:e172411. <https://doi.org/10.1001/jamaoncol.2017.2411>.
- [41] Galligioni E, Quaia M, Merlo A, Carbone A, Spada A, Favaro D, et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study. *Cancer* 1996;77:2560-6. [https://doi.org/10.1002/\(SICI\)1097-0142\(19960615\)77:12<2560::AID-CNCR20>3.0.CO;2-P](https://doi.org/10.1002/(SICI)1097-0142(19960615)77:12<2560::AID-CNCR20>3.0.CO;2-P).
- [42] Jocham D, Richter A, Hoffmann L, Iwig K, Fahlenkamp D, Zakrzewski G, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. *Lancet Lond Engl* 2004;363:594-9. [https://doi.org/10.1016/S0140-6736\(04\)15590-6](https://doi.org/10.1016/S0140-6736(04)15590-6).
- [43] Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. *Lancet Lond Engl* 2008;372:145-54. [https://doi.org/10.1016/S0140-6736\(08\)60697-2](https://doi.org/10.1016/S0140-6736(08)60697-2).
- [44] Chamié K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. *JAMA Oncol* 2017;3:913-20. <https://doi.org/10.1001/jamaoncol.2016.4419>.
- [45] Tsao C-K. Improvements Needed for Adjuvant Therapy in RCC 2020.
- [46] Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. *J Urol* 2002;168:2395-400. <https://doi.org/10.1097/01.ju.0000035885.91935.d5>.
- [47] Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. *J Clin Oncol Off J Am Soc Clin Oncol* 2001;19:1649-57. <https://doi.org/10.1200/JCO.2001.19.6.1649>.
- [48] Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. *Cancer* 2003;97:1663-71. <https://doi.org/10.1002/cncr.11234>.
- [49] Patard J-J, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study. *J Clin Oncol* 2004;22:3316-22. <https://doi.org/10.1200/JCO.2004.09.104>.
- [50] Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, et al. Validation of a new prognostic model to

- easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. *Ann Oncol Off J Eur Soc Med Oncol* 2017;28:2747-53. <https://doi.org/10.1093/annonc/mdx492>.
- [51] Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, et al. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. *Eur Urol* 2014;66:77-84. <https://doi.org/10.1016/j.eururo.2014.02.035>.
- [52] Rini B, Goddard A, Knezevic D, Maddala T, Zhou M, Aydin H, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. *Lancet Oncol* 2015;16:676-85. [https://doi.org/10.1016/S1470-2045\(15\)70167-1](https://doi.org/10.1016/S1470-2045(15)70167-1).
- [53] Morgan TM, Mehra R, Tiemeny P, Wolf JS, Wu S, Sangale Z, et al. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. *Eur Urol* 2018;73:763-9. <https://doi.org/10.1016/j.eururo.2017.12.002>.
- [54] Al-Qassab U, Lorentz CA, Laganosky D, Ogan K, Master V, Pattaras J, et al. PNFBA-12 LIQUID BIOPSY FOR RENAL CELL CARCINOMA. *J Urol* 2017;197. <https://doi.org/10.1016/j.juro.2017.02.3241>.
- [55] Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. *Eur Urol* 2011;59:543-52. <https://doi.org/10.1016/j.eururo.2010.12.013>.
- [56] Lim EA, Drake CG, Mintz A. Molecular imaging for cancer immunotherapy. *Immuno-Oncol Technol* 2020;5:10-21. <https://doi.org/10.1016/j.iotech.2020.03.001>.
- [57] Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. ⁸⁹Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med* 2018;24:1852-8. <https://doi.org/10.1038/s41591-018-0255-8>.
- [58] Griessinger CM, Olafsen T, Mascioni A, Jiang ZK, Zamilpa C, Jia F, et al. The PET-Tracer ⁸⁹Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment. *Cancer Res* 2020;80:2903-13. <https://doi.org/10.1158/0008-5472.CAN-19-3269>.
- [59] Harshman LC, Xie W, Moreira RB, Gustavo R, Sweeney C, Choueiri TK. Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC). *J Clin Oncol* 2017;35:459-459. https://doi.org/10.1200/JCO.2017.35.6_suppl.459.

Uncorrected Author Manuscript